DOCSLIB.ORG

Role of the SUMO Pathway in Acute Myeloid Leukemias Response to Treatments Hayeon Baik

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Role of the SUMO Pathway in Acute Myeloid Leukemias Response to Treatments Hayeon Baik Role of the SUMO pathway in Acute Myeloid Leukemias response to treatments Hayeon Baik To cite this version: Hayeon Baik. Role of the SUMO pathway in Acute Myeloid Leukemias response to treatments. Human health and pathology. Université Montpellier, 2017. English. NNT : 2017MONTT016. tel-01680009 HAL Id: tel-01680009 https://tel.archives-ouvertes.fr/tel-01680009 Submitted on 10 Jan 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Délivré par l’Université de Montpellier Préparée au sein de l’école doctorale CBS2 Sciences Chimiques et Biologiques pour la Santé Et de l’unité de recherche IGMM CNRS UMR5535 Institut de Génétique Moléculaire de Montpellier Spécialité Biologie-Santé Présentée par Hayeon BAIK Role of the SUMO pathway in Acute Myeloid Leukemias response to treatments Soutenue le 29 Juin 2017 devant le jury composé de Dr. Valérie Lallemand-Breitenbach Rapporteur Directrice de Recherche, INSERM, Paris Président du jury Pr. Stefan Müller Rapporteur Professeur, Université de Francfort Dr. Jean-Emmanuel Sarry Examinateur Chargé de Recherche, INSERM, Toulouse Dr. Guillaume Bossis Examinateur Chargé de Recherche, CNRS, Montpellier Dr. Marc Piechaczyk Directeur de Thèse Directeur de Recherche, CNRS, Montpellier 2 Acknowledgements I dedicate this thesis to my Heavenly Father, for all the blessings he has bestowed upon me. Foremost, I would like to acknowledge the members of the jury for evaluating my work and for coming to Montpellier: Valérie Lallemand-Breitenbach and Stefan Müller as ‘rapporteurs’, and Jean-Emmanuel Sarry as ‘examinateur’. I would like to express my sincerest gratitude to Dr. Marc Piechaczyk, my thesis director, for having accepted me in his laboratory, for his strong support, and his precious discussions. Sincere thanks go to Dr. Guillaume Bossis, for his sage advice, mentoring, and for his daily support. He made my Ph.D. experience productive and stimulated me to continue in research. It has been truly a privilege for me to have Marc and Guillaume as my supervisors in a project, which I really enjoyed. I am also grateful to Dr. Jean-Emmanuel Sarry and Dr. Martin Villalba for their valuable advices and careful guidance in my annual thesis committee meeting. I also thank Dr. Jean- Emmanuel Sarry for his deep engagement, his contribution to in vivo experiments and for having accepted me in his laboratory to follow these experiments. Great thanks to the “Oncogenesis and Immunotherapy” team. I was very happy to work with each of you. Your dedication, insightful criticism and help were so precious for me. Particular thanks go to Julie and Mathias for their contribution to my project. I wish to also express my appreciation to all members of the IGMM for being part of a wonderful working environment. In my daily work I have been really blessed with friendly and kind members of the IGMM. I am also very indebted to Tamara and Claire for their sincere sharing, laughing, crying in times of difficulties and happiness. I would also like to thank Sung-Muk Choi and Young-Suk Kim for their encouragements and prayers. Many people contributed to this thesis both for its scientific aspects as well as in daily life and I express my gratitude to them. Words cannot express the feeling, love and thankfulness I have for my family who supported and encouraged me during all my studies in France and in Madagascar. Finally, thank you Stephan, for your special dedication and support during my last year of PhD. Your presence was countlessly important. ☺ Thank you to all. Without you, my thesis would not have been accomplished. ☺ 3 4 Table of Contents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`1.,.$ ! P3 ! E#< ! /1'%Z !(!-%/, T,&($/)(,.%$()!'%0.L.+&!%L!,*+!1M.`1.,.$!L('.)H ! PY ! E#<#" ! /1'%!9@874:C! PY ! E#<#< ! /?58K>67:8C!4C_K54! PD ! E#<#E ! 04;?58K>6;4! PG ! E#<#P ! /1'%!J8C;4C;?;!587:A! 3I ! E#<#3 ! /1'%!.C74@6J7:CO!'87:A!R/.'V! 3" ! E#E ! ,(&[+,.$[!,*+! /1'% !-(,*a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ist of Figures ! L.[1&+!"Z!*+'(,%-%.+/./! "3 ! L.[1&+!<!Z!(!/,+-a./+!&+`1.&+'+$,!L%&!,&($/=&.-,.%$!L(=,%&/!01&.$[!'H+)%.0!! 0.LL+&+$,.(,.%$! "Y ! L.[1&+!EZ!$%&'()!'%$%=H,.=!0+^+)%-'+$,!.$!M%$+!'(&&%a! "D ! L.[1&+!PZ!$%&'()![&($1)%=H,.=!0+^+)%-'+$,!.$!M%$+!'(&&%a! "X ! L.[1&+!3Z!$%&'()!+&H,*&%.0!0+^+)%-'+$,!.$!M%$+!'(&&%a! "X ! L.[1&+!YZ!)+12+'.(!0+^+)%-'+$,! "G ! L.[1&+!DZ!=%&&+)(,.%$!M+,a++$!0.LL+&+$,!(')!L(M!/1M,H-+/!($0!=0P3b//=!0%,!-)%,!! -(,,+&$/! << ! L.[1&+!XZ!=H,%[+$+,.=!=)(//.L.=(,.%$!%L!(=1,+!'H+)%.0!)+12+'.(! <P ! L.[1&+!GZ!&+,.$%.0!'+,(M%)./'! E" ! L.[1&+!"IZ!'+=*($./'!%L!,&($/=&.-,.%$!&+[1)(,.%$!MH!&(&/! E< ! L.[1&+!""Z!.$01=,.%$!%L!(')!=+))!0.LL+&+$,.(,.%$!MH!$(,1&()!=%'-%1$0/!($0!! -*(&'(=+1,.=()/! E3 ! L.[1&+!"<Z!$1=)+%/%'+!/,&1=,1&+!($0!-&.$=.-()!'%0.L.=(,.%$!/.,+/!%$!*ES!*P!($0!0$(#! P" ! L.[1&+!"EZ!,*+!1M.`1.,.$!-(,*a(H#!L! P3 ! L.[1&+!"PZ!().[$+'+$,!%L!('.$%!(=.0!/+`1+$=+/!%L!/1'%T"S!/1'%T<S!/1'%TES!/1'%TP!($0!! /1'%T3! PY ! L.[1&+!"3Z!,*+!/1'%!-(,*a(H! PG ! L.[1&+!"Y!Z!L%&'(,.%$!%L!/1'%!=*(.$! PG ! L.[1&+!"DZ!/1'%!.$,+&(=,.$[!'%,.L/!R/.'/V! 3< ! L.[1&+!"XZ!/1'%!&+[1)(,+/!,&($/=&.-,.%$!,*&%1[*!'1),.-)+!'+=*($./'/! 33 ! L.[1&+!"GZ!0+&+[1)(,.%$/!%L!,*+!/1'%!-(,*a(H!.$!^(&.%1/!,H-+/!%L!=($=+&! 3D ! L.[1&+!<IZ!/1'%!=%$c1[(,.%$!&+[1)(,+/!,*+!L%&'(,.%$!($0!0./&1-,.%$!%L!-')T$M/! Y" ! L.[1&+!<"Z!&%/b/1'%!-(,*a(H!./!.$^%)^+0!.$!,*+!=*+'%&+/./,($=+!(')!=+))/! Y< ! L.[1&+!<<Z!/1'%T.$,+&(=,.$[!'%,.L!R/.'V!.$!=%&+/,"!./!&+`1.&+0!L%&!,&($/=&.-,.%$()!! &+-&+//.%$!%L!&(&!,(&[+,![+$+/! "I" ! L.[1&+!<EZ!(,&(!,&+(,'+$,!0+=&+(/+/![)%M()!/1'%H)(,.%$!.$!(')!=+))/! "IE ! L.[1&+!<PZ!'+(/1&+'+$,!%L!&%/! "<" ! L.[1&+!<3Z!)+^+)!%L!&%/!.$!(')!0.([$%/./!-(,.+$,/! "<< ! 9 List of Tables ,(M)+!"Z!L&+$=*T('+&.=($TM&.,./*!RL(MV!=)(//.L.=(,.%$!%L!(')!/1M,H-+/! << ! ,(M)+!<Z!^(&.($,!,&($/)%=(,.%$/!.$!(-)! <D ! ,(M)+!EZ!&+=1&&+$,)H!'1,(,+0!%&!,&($/)%=(,+0![+$+/!a.,*!+-.[+$+,.=!L1$=,.%$!.$!(')! <G ! ,(M)+!PZ!=H,%2.$+/!=($!.$01=+!0.LL+&+$,.(,.%$!%L!*1'($!'H+)%.0!)+12+'.(!=+))/! EP ! ,(M)+!3Z!,*+!/1'%H)(,.%$!'(=*.$+&H!.$!/#!=+&+^./.(+!($0!'(''()/! PD ! ,(M)+!YZ!=)(//.L.=(,.%$!%L!/+$-!./%-+-,.0(/+/! 3I ! ,(M)+!DZ!/1'%H)(,.%$!.$*.M.,%&/! 3E ! 10 Preamble Acute myeloid leukemia (AML) is one of the four types of primary leukemia’s, which is characterized by large increase in the number of myeloid precursor cells. These precursors have lost their ability to differentiate and accumulate in the bone marrow. AML is a very heterogeneous disease and most subgroups are treated by chemotherapy composed of a combination of two genotoxics: one anthracycline such as daunorubicin and the nucleoside analogue Ara-C. Unfortunately, a large number of patients relapse. In spite of many efforts in the development of novel chemotherapy, no significant improvement was observed in the survival rates during the past 40 years. Nevertheless, one minor group defined as acute promyelocytic leukemia (APL), is the only one subtype, which is now cured by a differentiation therapy with very high survival rate. It has been shown recently that many cancers have impaired regulation of small-ubiquitin like modifier (SUMO) pathway and this post-translational modification might serve as a new target in the treatment of cancer. When I arrived in the lab, I first participated to an ongoing study that concerned the role of the SUMO pathway in AML response to chemotherapeutic drugs and its involvement in chemoresistance. We have shown that chemotherapeutic drugs induce a massive desumoylation of cellular proteins through the ROS-dependent inactivation of the SUMO activating and conjugating enzymes.
Load more

Recommended publications
  • Activation of Smad Transcriptional Activity by Protein Inhibitor of Activated STAT3 (PIAS3)
    Activation of Smad transcriptional activity by protein inhibitor of activated STAT3 (PIAS3) Jianyin Long*†‡, Guannan Wang*†‡, Isao Matsuura*†‡, Dongming He*†‡, and Fang Liu*†‡§ *Center for Advanced Biotechnology and Medicine, †Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, and ‡Cancer Institute of New Jersey, 679 Hoes Lane, Piscataway, NJ 08854 Communicated by Allan H. Conney, Rutgers, The State University of New Jersey, Piscataway, NJ, November 17, 2003 (received for review August 22, 2003) Smad proteins play pivotal roles in mediating the transforming of many transcription factors through distinct mechanisms. growth factor ␤ (TGF-␤) transcriptional responses. We show in this PIAS1 and PIAS3 bind and inhibit STAT1 and STAT3 DNA- report that PIAS3, a member of the protein inhibitor of activated binding activities, respectively (19, 20). PIASx␣ and PIASx␤ STAT (PIAS) family, activates TGF-␤͞Smad transcriptional re- were identified through interactions with the androgen receptor sponses. PIAS3 interacts with Smad proteins, most strongly with and the homeodomain protein Msx2, respectively (21, 22). Smad3. PIAS3 and Smad3 interact with each other at the endog- PIASx␣ and PIASx␤ inhibit IL12-mediated and STAT4- enous protein level in mammalian cells and also in vitro, and the dependent gene activation (23). PIAS1, PIAS3, PIASx␣, and association occurs through the C-terminal domain of Smad3. We PIASx␤ also regulate transcriptional activation by various ste- further show that PIAS3 can interact with the general coactivators roid receptors (21, 24–26). PIASy has been shown to antagonize p300͞CBP, the first evidence that a PIAS protein can associate with the activities of STAT1 (27), androgen receptor (28), p53 (29), p300͞CBP.
    [Show full text]
  • An Immunoevasive Strategy Through Clinically-Relevant Pan-Cancer Genomic and Transcriptomic Alterations of JAK-STAT Signaling Components
    bioRxiv preprint doi: https://doi.org/10.1101/576645; this version posted March 14, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. An immunoevasive strategy through clinically-relevant pan-cancer genomic and transcriptomic alterations of JAK-STAT signaling components Wai Hoong Chang1 and Alvina G. Lai1, 1Nuffield Department of Medicine, University of Oxford, Old Road Campus, Oxford, OX3 7FZ, United Kingdom Since its discovery almost three decades ago, the Janus ki- Although cytokines are responsible for inflammation in nase (JAK)-signal transducer and activator of transcription cancer, spontaneous eradication of tumors by endoge- (STAT) pathway has paved the road for understanding inflam- nous immune processes rarely occurs. Moreover, the matory and immunity processes related to a wide range of hu- dynamic interaction between tumor cells and host immu- man pathologies including cancer. Several studies have demon- nity shields tumors from immunological ablation, which strated the importance of JAK-STAT pathway components in overall limits the efficacy of immunotherapy in the clinic. regulating tumor initiation and metastatic progression, yet, the extent of how genetic alterations influence patient outcome is far from being understood. Focusing on 133 genes involved in Cytokines can be pro- or anti-inflammatory and are inter- JAK-STAT signaling, we found that copy number alterations dependent on each other’s function to maintain immune underpin transcriptional dysregulation that differs within and homeostasis(3).
    [Show full text]
  • 1541-7786.MCR-09-0417.Full.Pdf
    Published Online First on April 6, 2010 Cell Cycle, Cell Death, and Senescence Molecular Cancer Research The Intracellular Delivery of a Recombinant Peptide Derived from the Acidic Domain of PIAS3 Inhibits STAT3 Transactivation and Induces Tumor Cell Death Corina Borghouts, Hanna Tittmann, Natalia Delis, Marisa Kirchenbauer, Boris Brill, and Bernd Groner Abstract Signaling components, which confer an “addiction” phenotype on cancer cells, represent promising drug tar- gets. The transcription factor signal transducers and activators of transcription 3 (STAT3) is constitutively ac- tivated in many different types of tumor cells and its activity is indispensible in a large fraction. We found that the expression of the endogenous inhibitor of STAT3, protein inhibitor of activated STAT3 (PIAS3), positively correlates with STAT3 activation in normal cells. This suggests that PIAS3 controls the extent and the duration of STAT3 activity in normal cells and thus prevents its oncogenic function. In cancer cells, however, the ex- pression of PIAS3 is posttranscriptionally suppressed, possibly enhancing the oncogenic effects of activated STAT3. We delimited the interacting domains of STAT3 and PIAS3 and identified a short fragment of the COOH-terminal acidic region of PIAS3, which binds strongly to the coiled-coil domain of STAT3. This PIAS3 fragment was used to derive the recombinant STAT3-specific inhibitor rPP-C8. The addition of a protein trans- duction domain allowed the efficient internalization of rPP-C8 into cancer cells. This resulted in the suppression of STAT3 target gene expression, in the inhibition of migration and proliferation, and in the induction of μ apoptosis at low concentrations [half maximal effective concentration (EC50), <3 mol/L].
    [Show full text]
  • Intricate SUMO-Based Control of the Homologous Recombination Machinery
    Downloaded from genesdev.cshlp.org on September 24, 2021 - Published by Cold Spring Harbor Laboratory Press REVIEW Intricate SUMO-based control of the homologous recombination machinery Nalini Dhingra and Xiaolan Zhao Molecular Biology Department, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA The homologous recombination (HR) machinery plays regulation in mammalian cells and highlight their simi- multiple roles in genome maintenance. Best studied in larities and differences with those found in yeast. It is the context of DNA double-stranded break (DSB) repair, noteworthy that SUMO plays important roles in modulat- recombination enzymes can cleave, pair, and unwind ing protein recruitment to damaged chromatin and in oth- DNA molecules, and collaborate with regulatory proteins er DNA break repair pathways. As these topics have been to execute multiple DNA processing steps before generat- well covered in other reviews (Schwertman et al. 2016; ing specific repair products. HR proteins also help to cope Garvin and Morris 2017), they are not addressed here in or- with problems arising from DNA replication, modulating der to maintain the focus on the regulation of core HR impaired replication forks or filling DNA gaps. Given machinery. these important roles, it is not surprising that each HR step is subject to complex regulation to adjust repair effi- ciency and outcomes as well as to limit toxic intermedi- Overview of the SUMO pathway and the effects ates. Recent studies have revealed intricate regulation of of sumoylation all steps of HR by the protein modifier SUMO, which SUMO, a small protein of ∼100 residues, is highly con- has been increasingly recognized for its broad influence served among eukaryotes with several isoforms found in in nuclear functions.
    [Show full text]
  • Abstract Book
    Abstract book WELCOME Dear participants, welcome to the 2010 International PhD Students Cancer Conference here at the IFOM-IEO Campus in Milan! We have tried to organize this conference at our best, hoping it will be an excellent opportunity to discuss about science, to meet new and interesting people and to broad our knowledge. We are very glad to host such an international meeting, with students coming from institutes all across Europe; moreover, this year we are very pleased to host students from the National Centre for Biological Sciences, Bangalore, India. We do hope you will find this conference really exciting and that you will have a great time here in Milan! Thank you all for coming!! The Organizers FOR ORGANIZATION REASONS, YOU ARE KINDLY REQUESTED TO ALWAYS WEAR/SHOW THE CONFERENCE BADGE! THANK YOU VERY MUCH FOR YOUR COLLABORATION! Federica Castellucci: [email protected] Francesca Milanesi: [email protected] Gianmaria Sarra Ferraris: [email protected] Chiara Segrè: [email protected] Gianluca Varetti: [email protected] International PhD Student Cancer Conference International PhD Student Cancer Conference 19th – 21st May 2010 IFOM-IEO Campus, Milan, Italy This is the fourth annual conference that is hosted and organized by students from the European School of Molecular Medicine (SEMM). The Conference will cover many topics related to cancer, from basic biology to clinical aspects of the disease. All attendees will present their research, by either giving a talk or presenting a poster. This conference is an opportunity to introduce PhD students to top cancer research institutes across Europe.
    [Show full text]
  • Enzymes Are Manufactured and Used by Bacteria in Order to Digest Waste
    Website: www.fermentor.co.in Food Beverages Textile Leather Agriculture Bio Pharma Effluent Treatment Enzyme : INTRODUCTION Protecting ecology is our duty. We are thus protecting our future generation. Waste water treatment has assumed great significance in today’s context where protecting the environment is a prime concern. The main objective of waste water treatment is to treat the effluent before it is discharged so that the environment is not polluted. Waste water treatment in general refers to treatment of suspended and floatable material, treatment of biodegradable organics and the elimination of pathogenic organisms. The contaminants in waste water are removed by physical chemical and biological means. These organisms are effectively removed by an enzyme called ENVIRO NZYME. ROLE OF AN ENZYME? An enzyme is a chemical catalyst that breaks up long, complex waste molecules (Hydrolytic reaction) into smaller pieces, which can then be digested directly by the bacteria. Enzymes are manufactured and used by bacteria in order to digest waste. ENVIRO NZYME – G a dry free flowing powder is a concentrated source of hydrolytic enzymes and eight strains of natural bacteria that are genetically capable of producing concentrations of enzymes in waste treatment systems under aerobic and anaerobic conditions. ENVIRO NZYME –G is used for reducing the BOD, COD levels as well as reducing the sludge volumes odour and colour in the effluent and sewage treatment plants. APPLICATION: This product finds application in industries like Agro Breweries &
    [Show full text]
  • The Role of Sumoylation of DNA Topoisomerase Iiα C-Terminal Domain in the Regulation of Mitotic Kinases In
    SUMOylation at the centromere: The role of SUMOylation of DNA topoisomerase IIα C-terminal domain in the regulation of mitotic kinases in cell cycle progression. By Makoto Michael Yoshida Submitted to the graduate degree program in the Department of Molecular Biosciences and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. ________________________________________ Chairperson: Yoshiaki Azuma, Ph.D. ________________________________________ Roberto De Guzman, Ph.D. ________________________________________ Kristi Neufeld, Ph.D. _________________________________________ Berl Oakley, Ph.D. _________________________________________ Blake Peterson, Ph.D. Date Defended: July 12, 2016 The Dissertation Committee for Makoto Michael Yoshida certifies that this is the approved version of the following dissertation: SUMOylation at the centromere: The role of SUMOylation of DNA topoisomerase IIα C-terminal domain in the regulation of mitotic kinases in cell cycle progression. ________________________________________ Chairperson: Yoshiaki Azuma, Ph.D. Date approved: July 12, 2016 ii ABSTRACT In many model systems, SUMOylation is required for proper mitosis; in particular, chromosome segregation during anaphase. It was previously shown that interruption of SUMOylation through the addition of the dominant negative E2 SUMO conjugating enzyme Ubc9 in mitosis causes abnormal chromosome segregation in Xenopus laevis egg extract (XEE) cell-free assays, and DNA topoisomerase IIα (TOP2A) was identified as a substrate for SUMOylation at the mitotic centromeres. TOP2A is SUMOylated at K660 and multiple sites in the C-terminal domain (CTD). We sought to understand the role of TOP2A SUMOylation at the mitotic centromeres by identifying specific binding proteins for SUMOylated TOP2A CTD. Through affinity isolation, we have identified Haspin, a histone H3 threonine 3 (H3T3) kinase, as a SUMOylated TOP2A CTD binding protein.
    [Show full text]
  • Modulation of STAT Signaling by STAT-Interacting Proteins
    Oncogene (2000) 19, 2638 ± 2644 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc Modulation of STAT signaling by STAT-interacting proteins K Shuai*,1 1Departments of Medicine and Biological Chemistry, University of California, Los Angeles, California, CA 90095, USA STATs (signal transducer and activator of transcription) play important roles in numerous cellular processes Interaction with non-STAT transcription factors including immune responses, cell growth and dierentia- tion, cell survival and apoptosis, and oncogenesis. In Studies on the promoters of a number of IFN-a- contrast to many other cellular signaling cascades, the induced genes identi®ed a conserved DNA sequence STAT pathway is direct: STATs bind to receptors at the named ISRE (interferon-a stimulated response element) cell surface and translocate into the nucleus where they that mediates IFN-a response (Darnell, 1997; Darnell function as transcription factors to trigger gene activa- et al., 1994). Stat1 and Stat2, the ®rst known members tion. However, STATs do not act alone. A number of of the STAT family, were identi®ed in the transcription proteins are found to be associated with STATs. These complex ISGF-3 (interferon-stimulated gene factor 3) STAT-interacting proteins function to modulate STAT that binds to ISRE (Fu et al., 1990, 1992; Schindler et signaling at various steps and mediate the crosstalk of al., 1992). ISGF-3 consists of a Stat1:Stat2 heterodimer STATs with other cellular signaling pathways. This and a non-STAT protein named p48, a member of the article reviews the roles of STAT-interacting proteins in IRF (interferon regulated factor) family (Levy, 1997).
    [Show full text]
  • AP Biology: Chemistry B Mcgraw Hill AP Biology 2014-15 Contents
    AP Biology: Chemistry B McGraw Hill AP Biology 2014-15 Contents 1 Carbohydrate 1 1.1 Structure .................................................. 1 1.2 Monosaccharides ............................................. 2 1.2.1 Classification of monosaccharides ................................ 2 1.2.2 Ring-straight chain isomerism .................................. 3 1.2.3 Use in living organisms ...................................... 3 1.3 Disaccharides ............................................... 3 1.4 Nutrition .................................................. 4 1.4.1 Classification ........................................... 5 1.5 Metabolism ................................................ 5 1.5.1 Catabolism ............................................ 5 1.6 Carbohydrate chemistry .......................................... 5 1.7 See also .................................................. 6 1.8 References ................................................. 6 1.9 External links ............................................... 7 2 Lipid 8 2.1 Categories of lipids ............................................ 8 2.1.1 Fatty acids ............................................. 8 2.1.2 Glycerolipids ........................................... 9 2.1.3 Glycerophospholipids ....................................... 9 2.1.4 Sphingolipids ........................................... 9 2.1.5 Sterol lipids ............................................ 10 2.1.6 Prenol lipids ............................................ 10 2.1.7 Saccharolipids ..........................................
    [Show full text]
  • Loss of Protein Inhibitors of Activated STAT-3 Expression in Glioblastoma Multiformetumors: Implications for STAT-3 Activation and Gene Expression Emily C
    Human Cancer Biology Loss of Protein Inhibitors of Activated STAT-3 Expression in Glioblastoma MultiformeTumors: Implications for STAT-3 Activation and Gene Expression Emily C. Brantley,1L. Burton Nabors,2 G. Yancey Gillespie,3 Youn-Hee Choi,5 Cheryl Ann Palmer,2,4 Keith Harrison,4 Kevin Roarty,1and Etty N. Benveniste1 Abstract Purpose: STATs activate transcription in response to numerous cytokines, controlling prolifera- tion, gene expression, and apoptosis. Aberrant activation of STAT proteins, particularly STAT-3, is implicated in the pathogenesis of many cancers, including GBM, by promoting cell cycle progres- sion, stimulating angiogenesis, and impairing tumor immune surveillance. Little is known about the endogenous STAT inhibitors, the PIAS proteins, in human malignancies.The objective of this study was to examine the expression of STAT-3 and its negative regulator, PIAS3, in human tissue samples from control and GBM brains. Experimental Design: Control and GBM human tissues were analyzed by immunoblotting and immunohistochemistry to determine the activation status of STAT-3 and expression of the PIAS3 protein.The functional consequence of PIAS3 inhibition by small interfering RNA or PIAS3 over- expression in GBM cells was determined by examining cell proliferation, STAT-3 transcriptional activity, and STAT-3 target gene expression.This was accomplished using [3H]TdR incorporation, STAT-3 dominant-negative constructs, reverse transcription-PCR, and immunoblotting. Results and Conclusions: STAT-3 activation, as assessed by tyrosine and serine phosphoryla- tion, was elevated in GBM tissue compared with control tissue. Interestingly, we observed expression of PIAS3 in control tissue, whereas PIAS3 protein expression in GBM tissue was greatly reduced.
    [Show full text]
  • Mapping of SUMO Sites and Analysis of Sumoylation Changes Induced by External Stimuli
    Mapping of SUMO sites and analysis of SUMOylation changes induced by external stimuli Francis Impensa,b,c, Lilliana Radoshevicha,b,c, Pascale Cossarta,b,c,1, and David Ribeta,b,c,1 aUnité des Interactions Bactéries-Cellules, Institut Pasteur, F-75015 Paris, France; bInstitut National de la Santé et de la Recherche Médicale, Unité 604, F-75015 Paris, France; and cInstitut National de la Recherche Agronomique, Unité sous-contrat 2020, F-75015 Paris, France Contributed by Pascale Cossart, July 22, 2014 (sent for review May 28, 2014) SUMOylation is an essential ubiquitin-like modification involved in Mapping the exact lysine residue to which SUMO is attached in important biological processes in eukaryotic cells. Identification of modified proteins is a critical step to get further insight into the small ubiquitin-related modifier (SUMO)-conjugatedresiduesinpro- function of SUMOylation. Indeed, the identification of SUMO teins is critical for understanding the role of SUMOylation but remains sites allows the generation of non-SUMOylatable mutants and the experimentally challenging. We have set up a powerful and high- study of associated phenotypes. Identification of SUMO sites by throughput method combining quantitative proteomics and peptide MS is not straightforward (8). Unlike ubiquitin, which leaves immunocapture to map SUMOylation sites and have analyzed changes a small diglycine (GG) signature tag on the modified lysine resi- in SUMOylation in response to stimuli. With this technique we iden- due after trypsin digestion, SUMO leaves
    [Show full text]
  • Sumoylation Is a Post-Translational Modification Regulating Skeletal Muscle Pathophysiology
    From the Department of Physiology and Pharmacology Karolinska Institutet, Stockholm, Sweden SUMOylation is a post-translational modification regulating skeletal muscle pathophysiology Gabriel Antonio Heras Arribas Stockholm 2020 All previously published papers were reproduced with permission from the publisher. Published by Karolinska Institutet. Printed by US-AB universitetsservice Cover: Mitochondrial distribution of GFP-tagged MuRF1 in murine myoblasts (C2C12) © Gabriel Antonio Heras Arribas, 2020 ISBN 978-91-7831-886-5 SUMOylation is a post-translational modification regulating skeletal muscle pathophysiology THESIS FOR DOCTORAL DEGREE (Ph.D.) By Gabriel Antonio Heras Arribas Principal Supervisor: Opponent: Associate Professor Stefano Gastaldello, PhD Assoc. Prof. Dorianna Sandoná Karolinska Institutet, Sweden Padova University, Italy Department of Physiology and Pharmacology Department of Biomedical Sciences Division of Pathophysiology of Striated Muscles Co-supervisor(s): Assistant professor Simone Codeluppi, PhD Examination Board: Karolinska Institutet, Sweden Prof. Nico Dantuma Department of Medical Biochemistry and Karolinska Institutet, Sweden Biophysics Department of Biomedical Sciences Dr. Nicola Cacciani Prof. Claes Andréasson Karolinska Institutet, Sweden Stockholm University, Sweden Department of Physiology and Pharmacology Department of Molecular Biosciences Division of Molecular Cell Biology Professor Lars Larsson Karolinska Institutet, Sweden Assoc. Prof. Johanna Lanner Department of Physiology and Pharmacology Karolinska Institutet, Sweden Department of Physiology and Pharmacology Division of Molecular Muscle Physiology and Pathophysiology To my wife Esther, thank you for pushing me to reach for the stars. To my parents Maria Pilar Arribas and Jose Antonio Heras, for being there every step of the way. “Do. Or do not. There is no try”. ABSTRACT The research of this thesis is focused to investigate the role of SUMOylation, a protein post-translational modification reaction, implemented to the skeletal muscle pathophysiology area.
    [Show full text]